Patient characteristics at initial diagnosis of chronic GVHD
Characteristic . | . | No. unknown . |
|---|---|---|
| Months from transplantation to diagnosis, median (range) | 3.9 (2.2-28.2) | 0 |
| Type of onset, no. (%) | 45 | |
| De novo | 103 (15) | |
| Quiescent | 501 (71) | |
| Progressive | 102 (14) | |
| Sites involved, no. (%) | ||
| Skin | 566 (75) | 1 |
| Eyes | 185 (25) | 9 |
| Mouth | 378 (51) | 5 |
| Liver | 249 (33) | 0 |
| Gastrointestinal tract | 340 (45) | 2 |
| Other* | 47 (6) | 1 |
| No. of sites involved (%) | 0 | |
| 1-2 | 432 (58) | |
| 3 | 246 (33) | |
| More than 3 | 73 (10) | |
| Dose of prednisone at diagnosis, mg/kg, no. (%) | 0 | |
| None | 280 (37) | |
| More than 0 but less than 0.5 | 220 (29) | |
| 0.5-1.0 | 155 (21) | |
| More than 1.0 | 96 (13) | |
| Platelet count less than 100 000/μL at diagnosis, no. (%) | 343 (46) | 2 |
| Serum bilirubin level more than 2 mg/dL at diagnosis, no. (%) | 121 (16) | 5 |
Characteristic . | . | No. unknown . |
|---|---|---|
| Months from transplantation to diagnosis, median (range) | 3.9 (2.2-28.2) | 0 |
| Type of onset, no. (%) | 45 | |
| De novo | 103 (15) | |
| Quiescent | 501 (71) | |
| Progressive | 102 (14) | |
| Sites involved, no. (%) | ||
| Skin | 566 (75) | 1 |
| Eyes | 185 (25) | 9 |
| Mouth | 378 (51) | 5 |
| Liver | 249 (33) | 0 |
| Gastrointestinal tract | 340 (45) | 2 |
| Other* | 47 (6) | 1 |
| No. of sites involved (%) | 0 | |
| 1-2 | 432 (58) | |
| 3 | 246 (33) | |
| More than 3 | 73 (10) | |
| Dose of prednisone at diagnosis, mg/kg, no. (%) | 0 | |
| None | 280 (37) | |
| More than 0 but less than 0.5 | 220 (29) | |
| 0.5-1.0 | 155 (21) | |
| More than 1.0 | 96 (13) | |
| Platelet count less than 100 000/μL at diagnosis, no. (%) | 343 (46) | 2 |
| Serum bilirubin level more than 2 mg/dL at diagnosis, no. (%) | 121 (16) | 5 |
Lung (n = 27), female genital tract (n = 8), and muscle or fascia (n = 6) were the most frequently affected sites.